Drugs / Penn Microbiome Therapy - 002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03970200 | Jan 2020 → Nov 2021 | Clostridium difficile colitis | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 2 | NCT03973697 | Jan 2020 → Aug 2021 | Clostridium difficile colitis | University of Pennsylvania | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Penn Microbiome Therapy - 002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03970200 ↗ |
| Route | Oral | “given by mouth in capsules or through a tube that goes into your stomach/intestines” NCT03970200 ↗ |
| Route | Other | “given by mouth in capsules or through a tube that goes into your stomach/intestines” NCT03970200 ↗ |